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IMPLEMENTING AN EDUCATIONAL 
RESOURCE ON CANNABIDIOL 









• Six patients inquired about CBD use during my first week at 
Brookfield Family Medicine in Brookfield, CT
• Patients reported hearing claims that it was beneficial for 
many conditions including arthritis, anxiety/depression, and 
chronic pain
• Many questioned the legality of CBD in the state of 
Connecticut 
• A CBD retailer had been operating over a year within a 
mile of the clinic 
• One provider at the practice told me he had recently had 
four patients in one day ask about CBD
• According the CDC, 23% of all adults in the US have some 
form of arthritis and more than 1 in 4 adults with arthritis 
report suffering from severe joint pain1
• Data from Anxiety and Depression Association of America 
reports that 40 million adults in the US suffer from an anxiety 
disorder2
• An estimated 1 in 5 adults in the US had chronic pain in 2016 




• CBD has become a popular consumer product over 
the last decade, especially as American consumers 
increasingly want more complementary and 
alternative medicines4
• However, CBD is not federally regulated and a 2017 
article from JAMA showed only 30% of CBD 
products were labelled accurately5
• Past UVM students have made pamphlets on patient 
education of CBD in Vermont, but there hasn’t been 
a pamphlet made specifically for consumers in 
Connecticut where regulations and need may differ14
• In addition, there is a lack of general public 
understanding regarding the efficacy, safety, and 
legality of this increasingly popular product
3A. PUBLIC HEALTH 
AND COST 
CONSIDERATIONS 
Arthritis contributes to $140 billion in direct medical 
costs annually1
Chronic pain contributes to $550 billion in direct 
medical costs each year in the US3
According to the National Institutes of Mental Health, 
National Survey on Drug Use and Health (NSDUH) in 
2016, it is estimated that 300,000 people in CT live with 
MDD, schizophrenia, or bipolar disorder7
The average cost of Anxiety annually in the US is 
between $42.3 billion and $46.6 billion with over 75% 
attributed to indirect costs2
4. COMMUNITY PERSPECTIVE ON ISSUE 
AND SUPPORT FOR PROJECT 
• “I do have a few patients who ask about it (CBD)… it is increasing… I mean 10 years ago no one 
was asking about it and now I’m starting to see it on patient’s med lists. Even I bought hemp 
shampoo/conditioner for my dog. Patients usually have questions for me like ‘is it safe? Do you 
think it works?’ Honestly, I don’t feel completely comfortable counseling them on it (CBD). I 
usually recommend looking up an honest website.”
- Jessica Stellato,  APRN,  Family Practice Nurse Practitioner 
• “I have 2 to 3 patients ask about it per week. 5 years ago no one asked about and now patients 
have a lot of questions about safety and whether it will be helpful for their specific complaint, 
things like pain… anxiety… I think there’s some data that it isn’t that helpful for 
anxiety/depression. I try to make them realize that this isn’t highly regulated, and patients need to 
take that into consideration. “
- Dr. Julia Auerbach, MD, Family Medicine Physician 
5. INTERVENTION 
AND METHODOLOGY 
• A pamphlet was created to educate patients on CBD use in 
Connecticut. This pamphlet included information on: 
• What CBD is and how it is derived from hemp
• Current legality status of CBD in the state of Connecticut 
• The validity of claims of CBD as backed by peer-reviewed research
• Considerations when purchasing CBD
• Answers to frequently asked questions
• Pamphlet was shared with the providers at the Brookfield Family 
Medicine Clinic and gone over in detail so they could properly educate 




• Pamphlet was made available to the providers at 
Brookfield Family Medicine. It was also distributed to 
the head of Family Medicine for the health network
• Responses from providers and patients was positive
• Providers appreciated having more information 
readily available to them when counseling patients 
on the pros and cons of CBD use
• Patients appreciated having information that they 
could take home with them 
• No formal data was collected from patients about 
the efficacy or quality of the pamphlet
• No formal data was collected on the effectiveness of the provided 
pamphlet due to time limitations
• Future surveys can guide what information should be in the pamphlet 
and what information may not be helpful
• There are many limitations regarding the effectiveness of the pamphlet 
• The pamphlet was only provided in English and may be inaccessible to 
non-English speakers 
• Future data collected can help guide who this pamphlet should be 
distributed to. Now, it’s given to those who ask about CBD but there 
may be patients who use CBD and are not disclosing this with their 
providers











Check in with the clinics using the pamphlet to ensure it is 
still being distributed to patients and if they are continually 
finding it helpful 
Update Update the pamphlet bi-annually to ensure the information remains up-to-date 
Provide
Provide a brief survey on knowledge of CBD to taken by 
patients before and after they read the pamphlet to evaluate 
effectiveness of the educational materials
Distribute Distribute the pamphlet to other primary care and specialty clinics within Connecticut
9. REFERENCES 
1. Centers for Disease Control and Prevention. (2019). How CDC Improves Life for People with Arthritis. Retrieved from 
://www.cdc.gov/chronicdisease/resources/publications/factsheets/arthritis.htm
2. Anxiety and Depression Association of America. (2019). Facts & statistics. Retrieved from https://adaa.org/about-adaa/press-room/facts-statistics 
3. Centers for Disease Control and Prevention. (2018). Prevalence of Chronic Pain and High-Impact Chronic Pain among Adults- United States, 2016. Retrieved from 
https://www.cdc.gov/mmwr/volumes/67/wr/mm6736a2.htm
4. Centers for Disease Control and Prevention. (2017). The Use of Complementary and Alternative Medicine in the United States. Retrieved from 
https://nccih.nih.gov/research/statistics/2007/camsurvey_fs1.htm
5. Bonn-Miller, M., et al. (2017) Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 318(17),1708-1709
6. The National Academies of Science, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids. Washington, D.C.: National Academies Press.
7. National Institutes of Mental Health, National Survey on Drug Use and Health (NSDUH) 2016, and NSDUH-MHSS 2008-2012. Estimated number of people affected based 
on total state population of 2,824,290 (18 years and over), Census Bureau data 
8. Devane, CL et al. (2005). Anxiety Disorders in the 21st Century: Status, Challenges, Opportunities, and Comorbidity With Depression. Am J Manag Care. 11(12), 344-353
9. Whiting, PF., Wolff, RF., Deshpande, S., et al. (2015). Cannabinoids for medical use. A systematic review and meta-analysis. JAMA. 313(24),2456-2473
10. American Academy of Family Physicians. (2019). Marijuana and Cannabinoids: Health, Research and Regulatory Considerations. Retrieved from 
https://www.aafp.org/about/policies/all/marijuana-cannabinoids.html
11. Connecticut Department of Consumer Protection. (2019). Hemp Manufacturing in Connecticut: Frequently Asked Questions. Retrieved from https://portal.ct.gov/-
/media/DCP/Hemp/CBD-HempFAQs_DCP.pdf
12. Russo, E. (2018). Cannabidiol Claims and Misconceptions. Trends in Pharmacological Sciences. 38(5), 499-500
13. Greyson, L., et al. (2018). An interaction between warfarin and cannabidiol, a case report. Epilepsy & Behavior Case Reports. 9, 10–11.
14. Pratt, Catherine G., "Educating Patients on Cannabidiol (CBD)" (2019). Family Medicine Clerkship Student Projects. 500. https://scholarworks.uvm.edu/fmclerk/500
